Trial Profile
A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs ACT 246475 (Primary)
- Indications Myocardial infarction
- Focus Biomarker; Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 06 Apr 2018 New trial record